DR Congo Ebola Cases Reach 10,668 as WHO Adds Two New Vaccines to Bundibugyo Trial


The Ebola outbreak in the Democratic Republic of the Congo has reached 10,668 confirmed cases and 5,198 deaths, the World Health Organization said on Saturday, making it the deadliest outbreak in the country's history and the second-largest Ebola outbreak ever recorded. The epidemic, declared in May, is caused by the Bundibugyo species of the virus — a strain for which there is no approved vaccine and no proven treatment. This week, in a significant step, the WHO backed adding two vaccines designed specifically for the Bundibugyo virus to an ongoing clinical trial in the country, the first time such vaccines will be evaluated during an active outbreak.

The latest numbers

The WHO's figures, covering the period through November 3, put the outbreak's case fatality ratio at 48.7 percent — nearly one in every two confirmed patients has died. Cases have been recorded in eight of the country's 26 provinces, and transmission remains active in 51 of the 67 affected health zones. Ituri province, in the conflict-affected northeast, remains the epicentre. The outbreak is the 17th recorded in DR Congo, and the Africa Centres for Disease Control and Prevention has described it as the fastest-growing in the country's history. UN figures as of November 1 already counted more than 10,500 confirmed cases and 5,126 deaths.

One statistic in the WHO's update points to the outbreak's central problem: of the 512 deaths reported since October 21, 335 occurred in communities and only 177 in treatment centres. The WHO expressed particular concern about community deaths among young children, attributing the trend to difficulties in detecting cases early and getting patients to care in time. Some areas have recorded a slight decline in cases, the organisation said, but "sustained and high-level transmission continues." Cases have also crossed borders — Kenya has confirmed nine cases and two deaths, and Nigeria one case — though the WHO said no new cases had been reported in Kenya or Nigeria since its October 23 update, while stressing the need for continued cross-border surveillance. Switzerland and the United Kingdom have medically evacuated confirmed cases involving their own citizens: a British doctor who contracted the virus while working on the response arrived in London on Thursday and is being treated at the Royal Free Hospital, the first confirmed case in a UK national during this outbreak. The WHO continues to advise against travel or trade restrictions.

Two vaccines designed for this strain join the trial

The Bundibugyo species is the gap in the world's Ebola defences. Vaccines and antibody treatments exist for the Zaire species, which caused the vast West African epidemic of 2014–2016, but nothing approved targets Bundibugyo. That is what makes this week's decision significant. On the recommendation of its independent Technical Advisory Group on Candidate Vaccines Prioritization, the WHO has backed adding two candidates to the Tumaini trial — "Tumaini" is Swahili for "hope" — which began on October 23 in Bunia, the capital of Ituri province, and is led by the DRC's National Institute for Biomedical Research.

The two candidates are ChAdOx1 BDBV, developed by the University of Oxford with the Serum Institute of India, and mRNA-1469, developed by the American company Moderna. Both were designed specifically against the Bundibugyo virus. The trial uses a ring-vaccination approach, offering vaccine to the contacts of confirmed patients, and its first arm is already testing whether the existing Ervebo vaccine — approved for the Zaire species, not for Bundibugyo — offers any cross-protection. "Last month, a vaccine trial began using the Ervebo vaccine, which is approved for Ebola virus, but not for Bundibugyo virus," WHO Director-General Tedros Adhanom Ghebreyesus told reporters. "Today, WHO expert groups are recommending adding two vaccine candidates to the trial." WHO officials said the new candidates could enter the trial within three to four weeks, once Congolese regulators give their approval, with initial results expected in early 2027. Tedros cautioned that vaccines alone would not end the outbreak, though they could become an important additional tool. A separate treatment trial, running since July, is testing whether the antibody MBP134, the antiviral remdesivir, or a combination of the two improves survival.

Violence and late detection are hampering the response

The outbreak's epicentre lies in one of the most insecure regions of the country, and this week the conflict directly struck the response. The UN Office for the Coordination of Humanitarian Affairs reported that dozens of civilians were killed overnight in eastern DR Congo, including at least 30 in the Cantine-Aloya locality of Beni Territory in North Kivu, where homes were burned and a health centre was destroyed. People who had been in contact with Ebola patients fled an observation centre, and response teams were forced to suspend operations in the area. Africa CDC Director-General Jean Kaseya has previously warned that continued transmission in DR Congo poses a direct threat to neighbouring countries.

The violence compounds the detection problem visible in the WHO's own figures. When a majority of deaths happen in the community rather than in treatment centres, it means patients are being found too late — or not at all — and each unmonitored case can seed new chains of transmission among family members and mourners before health workers know it exists.

Why it matters: what happens next

This outbreak is now testing the weakest point in global Ebola preparedness. For the Zaire species, the world has licensed vaccines and treatments that can be deployed within days. For Bundibugyo, it has none — and that absence is written through this epidemic's numbers, from the fatality rate of nearly 49 percent to the speed with which it became the second-largest Ebola outbreak on record. The Tumaini trial is therefore about more than this emergency: if either candidate proves effective, the world gains its first defence against a virus that has now demonstrated it can sustain a major epidemic.

But the timeline is unforgiving. Even if Congolese regulators approve the two candidates quickly, trial results are not expected until early 2027. The vaccines will not decide how this outbreak unfolds over the coming months. What will decide it is the unglamorous machinery of containment — surveillance, contact tracing, early isolation and safe burials — and that machinery is exactly what armed violence in the east keeps breaking, and what community deaths show is not yet reaching patients in time. The next things to watch are the speed of the DRC's regulatory approval, whether transmission in Ituri finally begins a sustained decline, and whether the outbreak remains within the region. On those, this week brought urgency, but not yet relief.

Sources

 

Comments

Popular posts from this blog

Sir Patrick Stewart Dies at 86: Star Trek's Captain Picard and X-Men's Professor X Remembered

"Healey's £20 Billion Bet: Chancellor Arms Britain's State Banks to Back AI, Defence and Green Energy"